Glioblastoma is one of the deadliest cancers.  Average life expectancy after diagnosis is 15 months.  There have been no meaningful therapeutic advances in nearly two decades.Princeton Oncotherapeutics has developed and patented a first-in-class membrane-disruptive metabolic agent, D-85, that, in cell line assays, induces rapid reactive oxygen species (ROS) generation and GBM cell collapse.D-85 comprises a mixture of compounds rather than a single molecule, alkylating agent or immune response antibody.D-85 shows promise in safely treating all forms of GBM cancer including types resistant to temozolomide (TMZ).